Assembly Biosciences, Inc. (NASDAQ:ASMB) Major Shareholder Alexander Schornstein Purchases 4,438 Shares

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Free Report) major shareholder Alexander Schornstein purchased 4,438 shares of the business’s stock in a transaction dated Friday, July 5th. The shares were purchased at an average price of $12.52 per share, with a total value of $55,563.76. Following the acquisition, the insider now directly owns 693,113 shares in the company, valued at $8,677,774.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Alexander Schornstein also recently made the following trade(s):

  • On Wednesday, July 3rd, Alexander Schornstein acquired 4,562 shares of Assembly Biosciences stock. The stock was acquired at an average price of $12.29 per share, with a total value of $56,066.98.

Assembly Biosciences Stock Up 0.4 %

NASDAQ:ASMB opened at $13.83 on Thursday. Assembly Biosciences, Inc. has a fifty-two week low of $7.69 and a fifty-two week high of $20.04. The company has a 50 day moving average price of $14.38 and a 200 day moving average price of $12.85.

Assembly Biosciences (NASDAQ:ASMBGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.74) by $1.08. The firm had revenue of $5.79 million for the quarter. On average, sell-side analysts anticipate that Assembly Biosciences, Inc. will post -12.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, May 10th. HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Thursday, June 20th.

Check Out Our Latest Stock Analysis on ASMB

Institutional Trading of Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Acuitas Investments LLC bought a new position in shares of Assembly Biosciences, Inc. (NASDAQ:ASMBFree Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 265,585 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Acuitas Investments LLC owned 0.40% of Assembly Biosciences as of its most recent SEC filing. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

(Get Free Report)

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

See Also

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with's FREE daily email newsletter.